Replimune down as FDA's top cancer drug regulator reportedly intervened in drug rejection
Source: SeekingAlpha
2025-08-04 06:57:54 ET
More on Replimune Group
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript
- Replimune Group: Analysts Are More Optimistic Than The Market
- Replimune surges as Cantor upgrades on possible FDA U-turn on lead drug
- Sarepta, Replimmune, Capricor rise as FDA’s biologics head departs
Read the full article on Seeking Alpha
For further details see:
Replimune down as FDA’s top cancer drug regulator reportedly intervened in drug rejection
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
7.97% G/L:
$5.02 Last:
609,269 Volume:
$4.90 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
